You are here: Industry Insights > Alzheimer

News List

Survey Finds Reducing Stigma Attributed To Alzheimer's Disease Vital To Prevention Research biospace
March 28, 2018
Stigma associated with Alzheimer's disease may be an obstacle for individuals to seek information about their risk of developing Alzheimer's disease and to participate in clinical studies that discover potential therapies
Charity forms Alzheimer’s disease taskforce pharmatimes
March 22, 2018
Alzheimer’s Research UK is calling on the NHS and the pharma industry to join its new taskforce to ensure people with dementia can access future treatments without unnecessary delay.
New Alzheimer's Association Report Reveals Sharp Increases in Alzheimer's Prevalence, Deaths and Cos biospace
March 21, 2018
Alzheimer's Association 2018 Alzheimer's Disease Facts and Figures report released today.
Invicro Launches AmyloidIQ to Advance Clinical Imaging Trials in Alzheimer’s Disease biospace
March 20, 2018
Invicro LLC, recently announced the launch of AmyloidIQ, a new and advanced algorithm that quantifies Amyloid scans for use in subject stratification and clinical trials of Alzheimer’s disease therapies.
Alzheon Launches IPO to Fund Alzheimer's Drug biospace
March 20, 2018
Alzheon, based in Framingham, Massachusetts, has filed with the U.S. Securities and Exchange Commission (SEC) to launch an initial public offering (IPO).
Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Me biospace
March 16, 2018
Biogen (Nasdaq: BIIB) Italy (March 15-18, 2018). AAT-AD/PD is a new joint meeting between the International Geneva/Springfield Symposium on Advances in Alzheimer’s Therapy and AD/PD™.
EIP Pharma Publishes Positive Alzheimer's Disease Clinical Study Data with Neflamapimod biospace
March 08, 2018
EIP Pharma LLC announced today that a 3-month phase 2a clinical trial showed that neflamapimod is a brain-penetrating small molecule that inhibits the intracellular enzyme p38 MAP kinase alpha (p38α)
FDA Issues New Draft Guidance for Alzheimer’s Trials that Could Open Up Approvals biospace
March 05, 2018
Merck & Company’s recent failure of verubecestat (MK-8931) in Alzheimer’s underlines just how difficult it has been for researchers to come up with meaningful treatments for the disease.
Meet the Unnoticed Alzheimer's Biotech Facing a Make-or-Break 2018 biospace
February 01, 2018
It seems that the primary news surrounding Alzheimer’s disease research has been nothing but negative for years. Phase III failures, discontinuing research and development have dominated the headlines.
Takeda/Zinfadel ends late-stage Alzheimer’s study pharmatimes
January 29, 2018
Alzheimer’s disease research has taken another hit with the termination of a Phase III study assessing the effect of diabetes drug pioglitazone on mild cognitive impairment (MCI) in patients with the condition.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page